| ||
| Breast cancer cases level off kjrh.com In 2002 a study revealed women taking hormone replacement therapy faced an increased risk for breast cancer and heart problems -- which triggered many women to ditch the drugs. NBC News reports experts at the American Cancer Society decided to ... See all stories on this topic » | ||
| Scientists discover first breast cancer oncogene in five years Laboratory Products News This is exciting because it's a prime candidate for the development of new breast cancer drugs designed specifically to target tumours in which this gene is overactive. Hopefully this will lead to more effective cancer treatments in the future." See all stories on this topic » | ||
| Roche's Avastin Rejected For Breast Cancer By UK Cost Body Automated Trader Besides the strong Swiss franc, Roche's reporting currency, the outlook reduction was mainly due to the fact that the US Food and Drug Administration last December said it plans to revoke the approval of Avastin in breast cancer because it doesn't ... See all stories on this topic » | ||
| Dragon-boat festival donates $65K Canada.com By Danielle Bell, Daily News February 28, 2011 State of the art equipment for women dealing with the threat of breast cancer is available in Nanaimo, thanks to a massive $65000 donation. The Dragon-boat festival Society and title sponsor Save-On-Foods ... See all stories on this topic » | ||
| ||
| Aetna HealthFund Consumer-Directed Plans Save Employers, Consumers Millions of ... Business Wire (press release) ... for breast and cervical cancer compared to members in PPO plans. In particular, diabetics in the Aetna HealthFund plans accessed screenings at higher rates than diabetic members in PPO plans; Used the prescription drugs to treat chronic conditions, ... See all stories on this topic » |
| ||
| Regulatory Recap: February 21 to February 27, 2011 - RegBlog By Penn Program on Regulation After planning to revoke its approval of Avastin, a drug used to treat breast cancer, the Food and Drug Administration grants a hearing to Genentech in which it will have the opportunity to persuade the FDA to hold off. ... RegBlog - http://www.law.upenn.edu/blogs/regblog/ | ||
| How Species Save Our Lives | OpenPCR - Open source, hackable PCR ... By tito asprin; most antibiotics; treatments for lymphoma and leukemia (Madagascar rosy periwinkle, pictured); lung, breast, and uterine cancer (Pacific yew tree, Arthur Barclay, a $1700000000 a year product today); rapamycin fungus found on Easter ... Beyond giving us powerful new drugs, discoveries from the natural world also frequently open our eyes to the unsuspected workings of our own bodies. One of the more obvious effects of being bitten by the South American pit viper, ... OpenPCR - Open source, hackable... - http://openpcr.org/ | ||
| pubget—the blog: Hot off the presses! May 01 Biomater By ian connor Compared with nontargeted LPD (NTLPD), TLPD-FCC showed significantly enhanced binding affinity and luciferase gene silencing activity in EGFR overexpressing MDA-MB-231 breast cancer cells in vitro. ... Gene and drug-delivery systems that use immobilization of carbohydrates are useful for the specific targeting of lectin-expressing tissues. Here, we report that N-acetylglucosamine (GlcNAc) with polyethylenimine (GlcNAc-PEI) specifically interacted with vimentin- expressing ... pubget—the blog - http://pubget.blogspot.com/ |
| ||
| Daiichi Sankyo Buys Plexxikon for Cancer Drug Pipeline - NYTimes.com Roche's unit Genentech and Daiichi Sankyo will jointly promote the drug once it is approved for sale, the statement said. Plexxikon has the breast cancer ... www.nytimes.com/2011/03/01/business/global/01drug.html | ||
| The Unhived Mind Ii -> Cancer drug Avastin 'not approved' for ... Cancer drug Avastin 'not approved' for breast cancers. The drugs watchdog said Avastin had 'no demonstrable benefit' 24 February 2011 Last updated at 10:21 ... z10.invisionfree.com/The_Unhived_Mind.../index.php?... |
Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment